Icosapent Ethyl

Category: pharmacological

Aliases: Vascepa

Pharmacological Mechanism

Ethyl ester of pure EPA (no DHA) — pharmaceutical grade ω-3. REDUCE-IT trial (2018) demonstrated 25% MACE reduction in statin-treated high-risk patients with elevated triglycerides. Mechanism beyond TG-lowering involves stabilization of atherosclerotic plaque + anti-inflammatory eicosanoid shift.

Half-Life (t½)

PO: 72h

Dosing Guidelines

• PO: Typical 4000mg (Range: 1000 - 4000 mg)

Target Organ Systems

• cardiovascular
• immune-hematologic